Media Coverage
Cell-Based Assays Keep Biosimilars on Track
The cell-based assay has become a mainstay of drug development, addressing new concerns raised by the advent of biologics. Whereas small molecule drugs may escape…
How Durham’s BioAgilytix courted a German bioanalytical lab
See the Triangle Business Journal’s feature on BioAgilytix’s acquisition of IPM Biotech.
Building Partnerships with Other CROs
By nature, the idea of CRO partnerships is attractive to Executives and Business Development Teams because such alignments equip their CRO with a more comprehensive,…
How to Win Client Trust as a CRO
The act of building trust with your pharmaceutical and biotech clients is similar to how trust is built between friends – both require time, mutual…
How to Set up a Successful CRO by Surrounding Yourself with the Right Team Members
It is very important for executives of CRO companies to recognize that the most critical factor in making a CRO successful is the people that…
Starting a CRO on Personal Credit
Bioanalysis Zone Regardless of the size of the CRO, the quality of the work that I received was most dependent on the specific team managing…
Evaluating the Immunogenicity of Antibody–drug Conjugates
Antibody–drug conjugates (ADCs) represent an innovative therapeutic approach that provides novel treatment options and hope for patients with cancer and infectious disease. In fact, ADCs…
Development and validation of an alpha fetoprotein immunoassay
Abstract Circulating alpha fetoprotein (AFP) is a diagnostic and prognostic biomarker for hepatocellular carcinoma (HCC) with potential utility as a pharmacodynamic endpoint in rodent tumor…
Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis
Abstract Pharmacokinetic properties of biotherapeutics are an important aspect of preclinical drug development. The lead identification and optimization space is characterized by aggressive timelines, large…